false FY 0001622244 http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember P5Y P5Y P10Y P10Y P5Y P5Y P5Y P5Y P5Y P5Y 0001622244 2023-01-01 2023-12-31 0001622244 2023-06-30 0001622244 2024-05-21 0001622244 2023-12-31 0001622244 2022-12-31 0001622244 us-gaap:RelatedPartyMember 2023-12-31 0001622244 us-gaap:RelatedPartyMember 2022-12-31 0001622244 us-gaap:NonrelatedPartyMember 2023-12-31 0001622244 us-gaap:NonrelatedPartyMember 2022-12-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2023-12-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2022-12-31 0001622244 OWPC:SeriesBConvertiblePreferredStockMember 2023-12-31 0001622244 OWPC:SeriesBConvertiblePreferredStockMember 2022-12-31 0001622244 2022-01-01 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2021-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2021-12-31 0001622244 us-gaap:CommonStockMember 2021-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001622244 OWPC:SubscriptionsPayableMember 2021-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001622244 us-gaap:RetainedEarningsMember 2021-12-31 0001622244 2021-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2022-12-31 0001622244 us-gaap:CommonStockMember 2022-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001622244 OWPC:SubscriptionsPayableMember 2022-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001622244 us-gaap:RetainedEarningsMember 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001622244 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001622244 OWPC:SubscriptionsPayableMember 2022-01-01 2022-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001622244 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001622244 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001622244 OWPC:SubscriptionsPayableMember 2023-01-01 2023-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001622244 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2023-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2023-12-31 0001622244 us-gaap:CommonStockMember 2023-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001622244 OWPC:SubscriptionsPayableMember 2023-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001622244 us-gaap:RetainedEarningsMember 2023-12-31 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-21 0001622244 OWPC:MergerAgreementMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember 2019-02-21 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2022-01-01 2022-03-31 0001622244 OWPC:OneWorldProductsIncMember 2023-01-01 2023-12-31 0001622244 OWPC:OWPVenturesIncMember 2023-01-01 2023-12-31 0001622244 OWPC:OneWorldPharmaSASMember 2023-01-01 2023-12-31 0001622244 OWPC:ColombianHopeSASMember 2023-01-01 2023-12-31 0001622244 OWPC:AgrobaseSASMember 2023-01-01 2023-12-31 0001622244 us-gaap:BuildingMember 2023-12-31 0001622244 us-gaap:OfficeEquipmentMember 2023-12-31 0001622244 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001622244 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001622244 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001622244 2023-12-22 2023-12-22 0001622244 srt:SubsidiariesMember 2023-12-31 0001622244 srt:SubsidiariesMember us-gaap:NonrelatedPartyMember 2023-12-31 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:MrJoergSommerMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:ThreeCorporateOfficersMember 2023-12-31 0001622244 OWPC:IsiahThomasIIIMember 2023-12-31 0001622244 OWPC:TimothyWoodsMember 2023-12-31 0001622244 OWPC:MrJoergSommerMember 2023-12-31 0001622244 OWPC:MrJoergSommerMember 2023-01-01 2023-12-31 0001622244 OWPC:MrJoergSommerMember OWPC:ClosingOfQualifiedOfferingMember 2023-01-01 2023-12-31 0001622244 OWPC:MrJoergSommerMember OWPC:RaisingTwoMillionMember 2023-12-31 0001622244 OWPC:MrJoergSommerMember OWPC:RaisingAnAdditionalOneMillionMember 2023-12-31 0001622244 OWPC:MrJoergSommerMember OWPC:RaisingAnAdditionalOneMillion1Member 2023-12-31 0001622244 OWPC:MrJoergSommerMember OWPC:RaisingAnAdditionalOneMillion2Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001622244 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001622244 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001622244 OWPC:RefundableDepositOnEquipmentPurchaseMember 2023-12-31 0001622244 OWPC:RefundableDepositOnEquipmentPurchaseMember 2022-12-31 0001622244 OWPC:DownPaymentonDistillationEquipmentMember 2023-12-31 0001622244 OWPC:DownPaymentonDistillationEquipmentMember 2022-12-31 0001622244 OWPC:SecurityDepositsOnLeasesHeldInColombiaMember 2023-12-31 0001622244 OWPC:SecurityDepositsOnLeasesHeldInColombiaMember 2022-12-31 0001622244 us-gaap:LandMember 2023-12-31 0001622244 us-gaap:LandMember 2022-12-31 0001622244 us-gaap:BuildingMember 2022-12-31 0001622244 us-gaap:OfficeEquipmentMember 2022-12-31 0001622244 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001622244 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001622244 us-gaap:FurnitureAndFixturesMember 2023-10-01 2023-10-01 0001622244 us-gaap:TrucksMember 2023-10-01 2023-10-01 0001622244 OWPC:OfficeFurnitureAndEquipmentMember 2022-08-15 0001622244 2022-08-15 2022-08-15 0001622244 2023-04-28 2023-04-28 0001622244 2022-01-02 0001622244 2021-12-27 2022-01-02 0001622244 2022-10-01 2022-10-01 0001622244 2022-10-01 0001622244 OWPC:RealPropertyLeaseAgreementMember 2021-08-27 2021-09-01 0001622244 OWPC:RealPropertyLeaseAgreementMember 2021-09-01 0001622244 OWPC:RealPropertyLeaseAgreementMember 2023-01-01 2023-12-31 0001622244 OWPC:RealPropertyLeaseAgreementOneMember 2022-06-01 2022-06-01 0001622244 OWPC:RealPropertyLeaseAgreementOneMember 2022-06-01 0001622244 OWPC:RealPropertyLeaseAgreementOneMember 2023-01-01 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember OWPC:PromissoryNoteMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember OWPC:PromissoryNoteMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-09-27 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-09-27 2022-09-27 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember OWPC:SeriesBCommonStockMember 2022-09-27 0001622244 OWPC:PromissoryNoteMember 2022-01-01 2022-12-31 0001622244 OWPC:PromissoryNoteMember 2023-01-01 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteEightMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteEightMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteNineMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteNineMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteElevenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteElevenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwelveMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwelveMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThirteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThirteenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourteenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFifteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFifteenMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNotesMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNotesMember us-gaap:RelatedPartyMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-11-28 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2023-10-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-09-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-14 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-08-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-08-02 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-06-13 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-06-13 2022-06-13 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-07-07 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-06-03 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-03-01 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-03-01 2022-03-01 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-02-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrJohnMcCabeMember 2022-02-15 2022-02-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2021-12-29 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2021-12-26 2021-12-29 0001622244 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001622244 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001622244 OWPC:AJBCapitalMember 2023-01-01 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember 2022-12-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:LDL8ConsultingLLCMember 2023-08-18 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:PurchaseAgreementMember 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:PurchaseAgreementMember 2023-06-23 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:AJBCapitalInvestmentsLLCMember 2023-06-23 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:AJBCapitalInvestmentsLLCMember 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:OneWorldPharmaSASMember 2022-09-15 2022-09-15 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:OneWorldPharmaSASMember 2022-09-15 0001622244 OWPC:UnsecuredPromissoryNoteFourMember OWPC:OneWorldPharmaSASMember 2022-06-17 2022-06-17 0001622244 OWPC:UnsecuredPromissoryNoteFourMember OWPC:OneWorldPharmaSASMember 2022-06-17 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember OWPC:OneWorldPharmaSASMember 2022-05-31 2022-05-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember OWPC:OneWorldPharmaSASMember 2022-05-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember 2022-05-30 0001622244 OWPC:UnsecuredPromissoryNoteSixMember OWPC:OneWorldPharmaSASMember 2022-05-30 0001622244 OWPC:UnsecuredPromissoryNoteSixMember OWPC:OneWorldPharmaSASMember 2022-05-30 2022-05-30 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember OWPC:OneWorldPharmaSASMember 2022-04-29 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember OWPC:OneWorldPharmaSASMember 2022-04-29 2022-04-29 0001622244 OWPC:AJBCapitalMember 2023-12-01 2023-12-07 0001622244 OWPC:NotespayableMember 2023-01-01 2023-12-31 0001622244 OWPC:NotespayableMember 2022-01-01 2022-12-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001622244 us-gaap:SeriesAPreferredStockMember OWPC:PreferredStockSalesMember 2023-01-04 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember 2023-01-04 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember OWPC:PreferredStockSalesMember 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember OWPC:PreferredStockSalesMember 2022-12-20 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember 2022-12-20 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember OWPC:PreferredStockSalesMember 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember 2023-07-01 2023-07-01 0001622244 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-01-01 0001622244 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001622244 us-gaap:SeriesBPreferredStockMember OWPC:SharePurchaseAgreementMember OWPC:TysadcoPartnersLLCMember 2022-09-01 2022-09-01 0001622244 us-gaap:SeriesBPreferredStockMember OWPC:SharePurchaseAgreementMember OWPC:TysadcoPartnersLLCMember 2022-09-01 0001622244 us-gaap:SeriesBPreferredStockMember 2022-09-11 2022-09-12 0001622244 us-gaap:SeriesBPreferredStockMember 2022-10-11 2022-10-12 0001622244 2022-10-11 2022-10-12 0001622244 OWPC:ELOCPurchaseAgreementMember OWPC:TysadcoPartnersLLCMember 2022-12-01 2022-12-31 0001622244 us-gaap:SeriesBPreferredStockMember OWPC:ELOCPurchaseAgreementMember OWPC:TysadcoPartnersLLCMember 2022-12-01 2022-12-31 0001622244 us-gaap:SeriesBPreferredStockMember 2023-11-16 0001622244 us-gaap:CommonStockMember 2023-11-16 0001622244 us-gaap:SeriesBPreferredStockMember 2023-09-12 0001622244 us-gaap:CommonStockMember 2023-09-12 0001622244 us-gaap:SeriesBPreferredStockMember 2023-07-07 0001622244 us-gaap:CommonStockMember 2023-07-07 0001622244 OWPC:TysadcoPartnersLLCMember OWPC:ELOCPurchaseAgreementMember 2022-09-01 2022-09-01 0001622244 OWPC:TysadcoPartnersLLCMember OWPC:ELOCPurchaseAgreementMember us-gaap:CommonStockMember 2022-09-01 2022-09-01 0001622244 OWPC:AdvisorAgreementMember 2023-08-22 2023-08-22 0001622244 srt:PresidentMember 2023-05-23 2023-05-23 0001622244 srt:PresidentMember srt:MaximumMember 2023-05-23 2023-05-23 0001622244 OWPC:AdvisorAgreementMember 2023-05-23 2023-05-23 0001622244 srt:PresidentMember us-gaap:CommonStockMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioOneMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioTwoMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioThreeMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioFourMember 2023-05-23 2023-05-23 0001622244 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001622244 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001622244 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001622244 2023-10-02 2023-10-02 0001622244 2023-10-02 0001622244 2023-02-14 2023-02-14 0001622244 2023-02-14 0001622244 us-gaap:CommonStockMember OWPC:SubscriptionPayableMember 2022-03-28 2022-03-29 0001622244 OWPC:PromissoryNoteMember OWPC:AJBCapitalInvestmentsLLCMember 2023-06-23 2023-06-23 0001622244 OWPC:AJBCapitalMember 2022-09-15 2022-09-15 0001622244 OWPC:AJBCapitalMember 2023-12-07 2023-12-07 0001622244 2023-11-21 2023-11-21 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember 2023-10-04 2023-10-04 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember 2023-09-18 2023-09-18 0001622244 OWPC:MrJoergSommerMember us-gaap:CommonStockMember 2023-06-15 2023-06-15 0001622244 OWPC:BoardOfDirectorsMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2020-02-11 2020-02-12 0001622244 OWPC:VaheGabrielMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-11-29 2023-11-29 0001622244 OWPC:VaheGabrielMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-11-29 0001622244 OWPC:ThreeAdvisoryBoardMembersMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-11-29 2023-11-29 0001622244 OWPC:ThreeAdvisoryBoardMembersMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-11-29 0001622244 OWPC:ThreeAdvisoryBoardMembersMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-01-01 2023-12-31 0001622244 OWPC:ThreeAdvisoryBoardMembersMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-12-31 0001622244 OWPC:ConsultantsMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-08-22 2023-08-22 0001622244 OWPC:SevenConsultantsAndEmployeesMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-08-22 0001622244 OWPC:SevenConsultantsAndEmployeesMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-08-22 2023-08-22 0001622244 OWPC:SevenConsultantsAndEmployeesMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2023-01-01 2023-12-31 0001622244 2023-01-01 0001622244 2022-01-28 0001622244 us-gaap:StockOptionMember 2021-12-31 0001622244 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001622244 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001622244 us-gaap:StockOptionMember 2022-12-31 0001622244 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001622244 us-gaap:StockOptionMember 2023-12-31 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-04-03 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2023-04-03 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-27 2023-01-27 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-27 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-01-27 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2023-01-27 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-09 2023-01-09 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-09 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-01-09 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2023-01-09 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-04 2023-01-04 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2023-01-04 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-01-04 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2023-01-04 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2022-12-21 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2022-12-21 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2022-12-20 2022-12-20 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember 2022-12-20 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-20 0001622244 us-gaap:SeriesAPreferredStockMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2022-12-20 0001622244 us-gaap:WarrantMember srt:MinimumMember 2023-01-01 2023-12-31 0001622244 us-gaap:WarrantMember srt:MaximumMember 2023-01-01 2023-12-31 0001622244 us-gaap:WarrantMember 2023-12-31 0001622244 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001622244 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001622244 us-gaap:WarrantMember 2021-12-31 0001622244 us-gaap:WarrantMember 2022-12-31 0001622244 us-gaap:SubsequentEventMember OWPC:SDTEquitiesLLCMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:SDTEquitiesLLCMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:PreFundedWarrantMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:PreFundedWarrantMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:DrKennethPeregoIIMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:DrKennethPeregoIIMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:SanguineGroupLLCMember 2024-03-04 0001622244 us-gaap:SubsequentEventMember OWPC:SanguineGroupLLCMember 2024-03-04 2024-03-04 0001622244 us-gaap:SubsequentEventMember OWPC:SanguineGroupLLCMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:JoergSommerMember 2024-03-19 2024-03-19 0001622244 us-gaap:SubsequentEventMember OWPC:JoergSommerMember 2024-03-19 0001622244 us-gaap:SubsequentEventMember OWPC:JoergSommerMember 2024-03-19 2024-03-19 0001622244 us-gaap:SubsequentEventMember OWPC:DrKennethPeregoIIMember 2024-01-08 2024-03-12 0001622244 us-gaap:SubsequentEventMember OWPC:DrKennethPeregoIIMember 2024-03-12 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-03-01 2024-03-01 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-03-01 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-03-01 2024-03-01 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-03-15 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-03-15 2024-03-15 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-01-29 2024-01-29 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-01-29 0001622244 us-gaap:SubsequentEventMember OWPC:DrJohnMcCabeMember 2024-01-29 2024-01-29 0001622244 us-gaap:SubsequentEventMember 2024-03-15 0001622244 OWPC:PromissoryNoteMember OWPC:AJBCapitalInvestmentsLLCMember us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001622244 OWPC:PromissoryNoteMember OWPC:MrJoergSommerMember us-gaap:SubsequentEventMember 2024-03-19 2024-03-19 0001622244 OWPC:PromissoryNoteMember OWPC:SanguineGroupLLCMember us-gaap:SubsequentEventMember 2024-03-04 2024-03-04 0001622244 us-gaap:SubsequentEventMember 2024-05-10 2024-05-10 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-10 2024-05-10 0001622244 OWPC:OfficersAndDirectorsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 OWPC:OfficersAndDirectorsMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 us-gaap:SubsequentEventMember 2024-02-09 2024-02-09 0001622244 OWPC:OfficersAndDirectorsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-02-09 2024-02-09 0001622244 OWPC:IsiahThomasIIIMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 OWPC:IsiahThomasIIIMember us-gaap:SubsequentEventMember 2024-05-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:SubsequentEventMember 2024-05-15 0001622244 OWPC:MrJoergSommerMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 OWPC:MrJoergSommerMember us-gaap:SubsequentEventMember 2024-05-15 0001622244 OWPC:DrJohnMcCabeMember us-gaap:SubsequentEventMember 2024-05-15 2024-05-15 0001622244 OWPC:DrJohnMcCabeMember us-gaap:SubsequentEventMember 2024-05-15 0001622244 2024-05-15 0001622244 OWPC:IsiahThomasIIIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 OWPC:IsiahThomasIIIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 0001622244 OWPC:TerryBuffaloIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 OWPC:TerryBuffaloIMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 0001622244 OWPC:MrJoergSommerMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 OWPC:MrJoergSommerMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 0001622244 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft OWPC:Integer iso4217:COP xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number: 000-56151

 

 

ONE WORLD PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

nevada   61-1744826
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

One World Products, Inc.

6605 Grand Montecito Pkwy., Suite 100

Las Vegas, Nevada 89149

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (800) 605-3210

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.

Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No

 

The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant based upon the closing price of $0.08225 per share as of June 30, 2023 was approximately $4,084,456.

 

As of May 21, 2024, there were 104,329,919 shares of registrant’s common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE: None

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I 1
Item 1. Business 1
Item 1A. Risk Factors 7
Item 1B. Unresolved Staff Comments 16
Item 1C. Cybersecurity 16
Item 2. Properties 16
Item 3. Legal Proceedings 16
Item 4. Mine Safety Disclosures 16
  PART II 17
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 17
Item 6. [Reserved] 18
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 24
Item 8. Financial Statements and Supplementary Data 25
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 26
Item 9A. Controls and Procedures 26
Item 9B. Other Information 26
  PART III 27
Item 10. Directors, Executive Officers and Corporate Governance 27
Item 11. Executive Compensation 29
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 30
Item 13. Certain Relationships and Related Transactions, and Director Independence 31
Item 14. Principal Accounting Fees and Services 33
  PART IV 34
Item 15. Exhibits and Financial Statement Schedules 34
SIGNATURES 35

 

 
 

 

PART I

 

Forward Looking Statements

 

This Form 10-K contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control.

 

These risks and uncertainties include our limited operating history; changes in cannabis laws, regulations and guidelines; our reliance on Colombian licenses, our ability to obtain authorizations and quotas; regulatory compliance risks; competition in our industry; our ability to establish and maintain bank accounts; our ability to comply with foreign trade policies; the continued demand for cannabis and derivate products; our ability to retain and acquire skilled personnel; and the risks involved in conducting operations in Colombia, as well as other factors set forth under the caption “Risk Factors” in this Form 10-K. Although the forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report. All written and oral forward-looking statements made subsequent to the date of this report and attributable to us or persons acting on our behalf are expressly qualified in their entirety by this section.

 

ITEM 1. BUSINESS

 

Overview

 

On February 21, 2019, we entered into an Agreement and Plan of Merger (“Merger Agreement”) with OWP Merger Subsidiary, Inc. (“OWP Merger Sub), our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”). Under the Merger Agreement, the acquisition of OWP Ventures by us was effected by the merger of OWP Merger Sub with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). The closing (the “Closing”) of the Merger occurred on February 21, 2019.

 

Immediately prior to the Closing, we were a public “shell” company with nominal assets. As of the Closing, we are no longer a public shell. As a result of the Merger, we are engaged in OWP Ventures’ business, including the business of its wholly-owned subsidiary, One World Pharma, S.A.S., a Colombian company (“OWP SAS”). On November 23, 2021, we changed our name from One World Pharma, Inc. to One World Products, Inc. through the merger of One World Products, Inc., a recently formed Nevada corporation wholly-owned by us, with and into us. This merger was effected solely to effect the change of our name, and had no effect on our officers, directors, operations, assets or liabilities.

 

On June 3, 2020, Isiah L. Thomas, III was appointed to serve as our Chief Executive Officer and Vice Chairman. Mr. Thomas was a 12-time NBA All Star, two-time NBA champion, and is an accomplished international business executive. In 2021, through ISIAH International, LLC, of which he is the sole member, Mr. Thomas purchased $3,000,000 of our Series B Preferred Stock in installments over a period of time ending in July 2021.

 

We plan to be a producer of and/or source raw and processed cannabis and hemp plant ingredients for both medical and industrial uses across the globe. The Company is a holding company and conducts its business in Colombia through OWP SAS, its wholly-owned subsidiary. OWP SAS has received licenses from the Colombian government to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes in the town of Esmeralda-Popayán, Cauca, Colombia.

 

On December 22, 2023, OWP SAS filed for for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia. The Reorganization Proceeds are similar to Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States, whereby the Company intends to restructure its debts. See “Operations of OWP SAS” for additional information.

 

We are in the process of acquiring another Colombian subsidiary within the Bogota free trade zone, which has all requisite licenses for the cultivation, production, distribution and export of cannabis and hemp infused products, and will serve as the Company’s primary base of operations in the Colombian market. Establishing operations within the free trade zone provides favorable import/export commercial terms and taxation, and will improve logistics and the overall operating efficiencies for the Company due to the close proximity of El Dorado International Airport and the commercial, economic and cultural center of the city of Bogota itself.

 

1

 

 

Operations of OWP SAS

 

We planted our first crop of cannabis in Popayán, Colombia in 2018, and began initial harvesting in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced. We commenced limited shipping of non-psychoactive products to customers in May of 2020. Subject to the completion of the Reorganization Proceedings, although we hold the four Colombian Licenses, we will need to obtain additional approvals from Colombian regulators before we can fully execute our business plan, particularly with respect to the sale psychoactive products. As described further under “Regulation” below,

 

  We will need to obtain quota approvals from the Colombian authorities before we can commence commercial sale of our psychoactive products under our Cannabis Manufacturing License and Psychoactive Cultivation License;
  We have successfully registered three non-psychoactive distinct cannabis strains and have received the certification required by Colombia’s National Registrar as of April 2020; and
  We have been issued the sanitary registrations needed to sell our products intended for human consumption; and
  We have successfully registered eight psychoactive distinct cannabis strains and have received the certifications required by Colombia’s National Registrar as of December 2020; and
  We will proceed to get quota approvals for 2024.

 

Our first cultivation site was located in Popayán, Colombia. Our cultivation facility encompassed approximately 30 acres and included a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we entered into agreements with a local farming co-operative that cultivated cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sold their harvested products to us on an exclusive basis.

 

We employ modern propagation and cultivation techniques drawn from U.S. practices that allow us to rapidly multiply the cells of a specific plant strain to produce large numbers of genetically consistent progeny plants using our own plant tissue culture method. We believe this technique allows us to cultivate plants which are stable, robust and able to produce genetically superior cannabis and hemp derived products. We intend to have our processes and products certified as compliant with international standards, including Good Agricultural Practices (“GAP”), Good Manufacturing Practice (“GMP”) and the standards set forth in EU Pharmacopoeia, a publication that sets forth quality standards applicable to the European pharmaceutical industry.

 

We generated revenues since the second quarter of 2020. Between August 2021 and March 2022, we made payments of approximately $1,400,000 for the purchase of a state-of-the-art distillation machine that cleared customs and is currently located in a warehouse near Bogota. We intend to build out an extraction and production facility in the Bogota free trade zone extension, after we execute a lease for this location. The installation of this equipment makes us one of the only companies in Colombia to both hold licenses and possess the capability to extract high-quality CBD and THC oils.

 

For strategic and operational reasons, OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary regulations governing Reorganization Proceedings in Colombia, on December 22, 2023. Subject to court approval, the Company intends on continuing its normal operations during the Reorganization Proceeding. Our normal operations consist or providing cannabinoids in bulk for the domestic and international markets, including the raw material for our brands and affiliate companies. At this time, the Company cannot predict the length of time of the Reorganization Proceeding. The Company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings to include the petitioning entity, OWP SAS, as well as the Company’s non-operating shell entities, Agrobase, S.A.S. and Hope Colombia, S.A.S., given the lack of independently identifiable operations. The deconsolidation resulted in a loss on deconsolidation of foreign subsidiaries in the amount of $1,564,823 for the year ended December 31, 2023.

 

We expect to start exporting products in 2024, including CBD flower and distillate oil, while developing white label commercial agreements with partners in Europe, USA, and Latin America. Our product pipeline may include premium coffee certified by the Colombian National Coffee Federation infused with CBD, teas infused with CBD and a series of wellness products, including sports CBD energy drinks for optimum performance, CBD facial and body creams for anti-inflammatory and anti-aging use. In September and December 2023, we entered into strategic partnerships with Smokiez Edibles to distribute Smokiez Gummies in Colombia and other countries in Latin America. In December 2023, we entered into a strategic partnership with Kx Family Care, which honors the legacy of Bob Marley to distribute Kx Family Care products in Colombia and other countries in Latin America. There can be no assurances that these strategic partnerships will generate revenue or be profitable for the Company.

 

History and Background

 

One World Pharma S.A.S., is a Colombian company (“OWP SAS”), incorporated on July 14, 2017 with the goal of procuring the following Colombian Licenses.

 

2

 

 

On December 20, 2017, the Colombian Ministry of Health, by means of resolution No. 5251 of 2017, granted OWP SAS its license for the production of cannabis derivatives for domestic use and export, allowing OWP SAS to extract high tetrahydrocannabinol (“THC”) compounds (“Cannabis Manufacturing License”). This license will expire on December 20, 2027.

 

On December 26, 2017, the Colombian Ministry of Justice, by means of resolution No. 1087 of 2017, granted OWP SAS its license to use seeds for sowing for sale or delivery of seeds and/or for scientific research purposes, allowing for genetic and seed bank registration (“Cannabis Seed Possession License”). This license will expire on December 26, 2027.

 

On December 26, 2017, the Colombian Ministry of Justice, by means of resolution No. 1088 of 2017, granted OWP SAS its license to grow non-psychoactive cannabis plants (less than 1.0% THC). Under this license, OWP SAS can produce seeds for planting, deliver and make sales of the cannabis crop in order to produce cannabis derivatives and deliver and make sales of the cannabis crop for industrial purposes (“Cannabis Non-Psychoactive Cultivation License”). This license will expire on December 26, 2027.

 

On January 4, 2018, the Colombian Ministry of Justice, by means of resolution No. 0015 of 2018, granted OWP SAS its license to grow psychoactive cannabis plants (greater than 1.0% THC) (“Psychoactive Cultivation License”). Under this license, OWP SAS can produce seeds for planting, and deliver and make sales of the cannabis crop in order to produce cannabis derivatives. This license will expire on January 4, 2028.

 

Six months prior to the expiration of each of the Licenses, we can apply for successive renewals for additional five-year periods. In each renewal application, the corresponding Ministry will assess compliance with all the relevant requirements in determining whether or not to renew the License.

 

On March 27, 2018, OWP Ventures, Inc. was formed as a Delaware corporation for the purpose of acquiring OWP SAS.

 

On May 30, 2018, OWP Ventures entered into a Stock Purchase Agreement with the shareholders of OWP SAS whereby the shareholders of OWP SAS transferred their shares in OWP SAS to OWP Ventures in exchange for 10,200,000 shares of common stock of OWP Ventures.

 

Products

 

Our business involves the cultivating, processing and supplying crude cannabis oil, distillate and isolate to customer specifications. We plan to sell as a wholesaler to industrial companies making cannabis related products as well as other products through retail and other distribution channels. We also plan on supplying the hemp plant bio-mass remaining after our extraction process to industry participants that utilize hemp in the manufacture of their products. Hemp is used to make a variety of commercial and industrial products, including rope, textiles, clothing, shoes, food, paper, bioplastics, insulation and biofuel.

 

We have registered 25 varieties or strains of cannabis with the Colombian Ministry of Health. See “Strains of Cannabis” below. The development of these strains enables us to select mother plants and identify the concentrations of cannabinoids required for the products which we intend to distribute. The cannabis will be produced in accordance with GMP Standards. We are committed to developing final products consistent with medicinal cannabis industry standards and pharmaceutical procedures. Our products will include a variety of cannabinoids and terpenes designed to address specific medical conditions. The composition of the strains will include a wide range of THC and CBD ratios.

 

3

 

 

Industry

 

Medicinal cannabis refers to the use of cannabis and its constituent cannabinoids and terpenes to treat disease or ameliorate symptoms such as pain, muscle spasticity, nausea and other indications. Cannabinoid is a blanket term covering a family of complex chemicals, both natural and man-made, that bind with cannabinoid receptors (protein molecules on the surface of cells) and effect a wide number of responses. Cannabinoid receptors in the human body are part of a system called the endocannabinoid system. This system produces chemicals called endocannabinoids, which also bind with cannabinoid receptors. Cannabinoid receptors are found in the brain and throughout the body. Scientists have found that cannabinoid receptors in the endocannabinoid system are involved in a vast array of functions in our bodies, including helping to modulate brain and nerve activity (including memory and pain), energy metabolism, heart function, the immune system and even reproduction. While there are a large number of active cannabinoids found in cannabis, the two most common currently used for medical purposes are tetrahydrocannabinol and cannabidiol. Although no clinical trials have been completed in the United States to validate the effectiveness of tetrahydrocannabinol or cannabidiol in managing disease and improving symptoms, scientific studies have identified that they, alone and/or in combination, may potentially provide treatment benefits for a large number of medical conditions. For example, tetrahydrocannabinol, a psychotropic cannabinoid, has been shown to activate pathways in the central nervous system which work to block pain signals and has shown potential to assist patients with Post Traumatic Stress Disorder (PTSD) and stimulate appetite in patients following chemotherapy. Cannabidiol, on the other hand, is non-psychotropic and has shown potential to relieve convulsion and inflammation, and is the active ingredient in Epidolex, which in June 2018 was approved by the FDA for the treatment of two rare and severe forms of epilepsy.

 

Regulation

 

Our primary active business operations are currently conducted solely within Colombia, and as such, the discussion below is limited to Colombian laws and regulations applicable to our business, which require us to hold the relevant licenses, quotas and other permits, as described below. Our activities in the United States consist of corporate administrative activities at our Las Vegas, Nevada headquarters, including accounting, finance and SEC compliance functions, and preliminary research and development activities of hemp fiber applications and products in the Detroit, Michigan area. We believe that our current activities in the United States will not subject us to regulation under the U.S. Controlled Substances Act or other applicable U.S. federal or state laws with respect to our proposed business plans. All export activities will be conducted from Colombia, and we do not intend to export any of our products to jurisdictions where such sales are not legal under local law. Accordingly, we do not currently intend to export our products to the United States to the extent such products may be subject to regulation under the U.S. Controlled Substances Act or other applicable U.S. federal or state regulations.

 

Regulatory Authorities

 

Several authorities interact in the Colombian cannabis industry. The Ministry of Health is in charge of granting the Cannabis Manufacturing and Distribution License and exercises administrative control over the production of cannabis derivatives. The Ministry of Justice, through the subsection for the Control and Supervision of Chemical Substances and Narcotic Drugs, is the competent authority for issuing the Cannabis Seeds Possession License, the Cannabis Psychoactive Cultivation License and the Cannabis Non-Psychoactive Cultivation License and for exercising administrative control over cannabis operations and cultivation. The National Narcotics Fund (“FNE”) exercises administrative and operational control over activities related to the management of psychoactive and non-psychoactive cannabis and its derivatives. The National Food and Drug Surveillance Institute (“INVIMA”) is in charge of issuing and monitoring compliance under the health and phytosanitary registrations that may be applicable to products containing cannabis derivatives. The Colombian Agricultural Institute (“ICA”) is responsible for maintaining the registry of the Genetic Pool or ¨Fuente Semillera” and the registration of cannabis seeds and strains under the “Registro Nacional de Cultivares Comerciales”.

 

In exercising the administrative and operational control activities discussed above the Ministry of Justice, Ministry of Health, ICA and FNE are required to coordinate their activities to the extent necessary, according to their competencies, with the Ministry of Agriculture and Rural Development through ICA, as well as with the National Police.

 

Licenses

 

Under Colombian law, there are four types of cannabis licenses that authorize different activities concerning the various stages of the production line of the medical cannabis industry: (i) the Cannabis Seeds Possession License; which is required for the domestic sale and delivery of seeds (but not export) and for scientific research purposes; (ii) the Cannabis Psychoactive Cultivation License, which is required for the production of seeds for sowing; for grain production; production of cannabis derivatives; for scientific research purposes, for storage, and for final disposal; (iii) the Cannabis Non-Psychoactive Cultivation License, which is required for the production of grain and seeds for sowing; production of cannabis derivatives; for industrial purposes; for scientific research purposes; for storage; and for final disposal; and (iv) the Cannabis Manufacturing and Distribution License, which is required for the production of cannabis derivatives for domestic use; production of cannabis derivatives for scientific research purposes; and production of cannabis derivatives for exportation. OWP SAS holds all of these licenses.

 

4

 

 

The legal framework currently in force in Colombia regarding medical cannabis is established in Law 1787 of 2016 (the “Law”) and the Decree 613 of 2017 (the “Decree”). Cannabis licenses must be issued by the Ministry of Health or the Ministry of Justice in an estimated time of 60 days, however, in practice, this process can take between four and six months. In accordance with Colombia’s international obligations, there is a limit in the amount of Cannabis allowed for fabrication or cultivation assigned by the Colombian Government (specific crop or manufacturing quotas) that must be requested by each licensee when applying for a Cannabis Psychoactive Cultivation License or a Cannabis Manufacturing License. The activities of cultivation and manufacturing can only be started once the specific quotas have been granted to the licensee.

 

Duration of Licenses

 

The Cannabis Seeds Possession License, the Cannabis Psychoactive Cultivation License, the Cannabis Non-Psychoactive License, and the Cannabis Manufacturing and Distribution License are granted by the Ministry of Justice and/or the Ministry of Health (as applicable), when the applicant fulfills the general criteria described in Article 2.8.11.2.1.5 of the Decree, and the specific requirements for each type of license. Each of these licenses is valid for up to five years. The Ministry of Justice and the Ministry of Health (as applicable) maintain the right to monitor the activities performed by the corresponding licensee, and in the event of a breach by the licensee of the obligations and duties set forth in the Decree, the licenses may be revoked. The relevant Ministry may renew these licenses for additional and successive five-year periods. In each renewal application, the Ministry will assess compliance with all the relevant requirements in determining whether or not to renew the license.

 

Quotas

 

As described above, regulations of cannabis in Colombia provides an additional requirement applicable to the Cannabis Psychoactive Cultivation License and Cannabis Manufacturing License, which require the grant of crop and manufacturing quotas (the “Quotas”). According to Article 2.8.11.2.6.2 of the Decree, the assignment of Quotas is collectively made by the Ministry of Health, the Ministry of Justice, the ICA, the INVIMA, and the FNE.

 

According to Article 2.8.11.2.6.5 of the Decree, there are two types of Quotas: (i) crop quotas for psychoactive cannabis (for holders of the Cannabis Psychoactive Cultivation License) which are granted by the Ministry of Justice; and (ii) the manufacturing quotas for psychoactive cannabis (for holders of the Cannabis Manufacturing License) which are granted by the Ministry of Health.

 

These Quotas are requested by the licensees no later than the last calendar day of April of each year, and, if they are granted by the corresponding authority, they can only be used by the licensees during the next calendar year (for instance, if a licensee requests a specific crop Quota in March, 2018, and this Quota is granted by the Ministry of Justice, the licensee will be allowed to use the Quota from January 1, 2019 to December 31, 2019). In extraordinary events, the licensees can request a supplementary Quota that will apply to the calendar year requested (the issuance of these Quotas depends on the special circumstances defined by the Colombian governmental authorities).

 

On December 3, 2018, by means of resolution 1256 of 2018, Colombia´s Ministry of Justice granted OWP SAS a supplementary Quota for growing psychoactive mother plants; six for each of 13 varieties, for a total of 78 “mother” plants. However, before we commence the commercial sale of our psychoactive products (greater than 1% THC content), we will need to obtain Quotas from the Ministry of Health. This will require us to conduct successful agricultural characterization tests approved by and registered with the ICA/Ministry of Agriculture and Rural Development, and stabilized extracts characterization tests approved by INVIMA/Ministry of Health, of product samples grown by us under Quotas obtained from the Ministry of Justice. We have already requested from the Ministry of Health and Justice our annual Quotas for the export sale of psychoactive ingredients in 2022, and are awaiting the issuance of such Quotas in order to start our production process.

 

Strains of Cannabis

 

Strains of cannabis are registered in Colombia in two manners:

 

  Registration of the Genetic Pool or “Fuente Semillera”: Under Article 2.8.11.11.1 of the Decree, licensed producers of cannabis had until December 31, 2018 to register the genetics of strains of cannabis with the ICA. Under this transitory article, the government allowed a limited period for licensed producers of cannabis to source genetics currently available in Colombia and register these as their “fuente semillera”. We registered 25 varieties under this article. This registration enables us to grow our own strains of cannabis as opposed to having to purchase registered strains from other licensed producers.

 

5

 

 

  Registration Under the “Registro Nacional de Cultivares Comerciales”: Licensed producers of cannabis have to be granted a breeding/research license to be able to develop, select and trial stabilized cannabis cultivars. This registration allows licensed producers to register unique and stable varieties of cannabis for commercial production within Colombia. We were granted such license in the first quarter of 2018. Licensed producers can then request from ICA a registration trial, which is a field flowering trial with the supervision of ICA officials. The data collected in these trials can lead to registration of the cultivar in the National Registrar. Only registered varieties will be allowed to be produced commercially. We have received full registration for 3 non-psychoactive high CBD strains which have been approved for sale. We have also received permission to take 13 psychoactive THC strains through this process. In 2023, we maintained the registered varieties allowed for commercialization.

 

Sanitary Registration

 

The commercialization of cannabis-based finished products intended for human consumption requires the issuance of sanitary registrations by the INVIMA, and in the case of products intended for animal consumption, by the ICA.

 

Environmental

 

Under Colombian law, general principles of environmental law are set out in Law 99 of 1993 and Article 9 of the National Code of Natural Resources and Protection of the Environment. These laws establish principles governing the use of natural resources, including that use must occur without causing harm to the interests of the community or of third parties. Parties that cause environmental damage while acting under the authority of a permit are responsible for incurring the costs to rectify the damage. The imposition of environmental sanctions is in addition to civil and criminal penalties that may be imposed. Environmental damage caused while a party is acting without a license constitutes a breach of Law 99 of 1993 and may lead to the imposition of sanctions, in addition to civil or criminal proceedings that may result. Parties that cause environmental damage, in addition to sanctions or penalties that apply, will also be required to carry out studies to assess the characteristics of the damage. Under Colombian law, liability for environmental damage creates a presumption of liability in case of a: (i) breach of environmental laws; (ii) environmental damage; and (iii) breach of environmental license or any other administrative act from the environmental authorities. The Environmental Authorities may investigate potential claims, authorize preventative measures, or impose sanctions on parties breaching environmental law.

 

Competition

 

The market for medicinal cannabis is characterized by unsatisfied patient demand, with few authorized producers. Although competition in the market is growing and Colombia offers an open process to apply for the licenses, we believe we are competitively positioned to satisfy the demand for medicinal cannabis given our early entry into the market, the management team’s expertise in medical product branding, marketing, quality control and domestic market relationships. In addition, the Colombian government has published for comment a draft decree that requires any applicant for any of the four Licenses to furnish evidence that it has completed the seed registration process before the ICA and obtained the corresponding technical sheet for the cannabis plants and varieties. If enacted, this new regulation will result in stricter requirements on potential competitors seeking a Colombian License.

 

Cultivation in Colombia has natural cost advantages. However, management believes the more sustainable competitive advantage is to create patient loyalty and brand preference, as opposed to the distribution of more homogeneous products. Domestically our competition consists of PharmaCielo, CannaVida, Empresa Colombiana de Cannabis, Khiron Life Sciences Corp., MedCan, Canopy Growth Corporation, and Clever Leaves.

 

Intellectual Property

 

Our success depends, at least in part, on our ability to protect our core technology and intellectual property. To accomplish this, we rely on trade secrets, including know-how, employee and third-party nondisclosure agreements and other contractual rights to establish and protect our proprietary rights in our technology.

 

Seasonality

 

Colombia and its vertical offering of microclimates is the ideal country for year-round growing and processing of all possible varieties of cannabis in a natural, environmentally friendly manner.

 

6

 

 

Principal Executive Offices

 

Our principal executive offices are located at 6605 Grand Montecito Pkwy, Suite 100, Las Vegas, Nevada 89149. Our telephone number is (800) 605-3210. We believe our facilities are adequate to meet our current and near-term needs.

 

Employees

 

As of December 31, 2023, we had 10 full-time employees. Since inception, we have never had a work stoppage, other than due to the Covid-19 quarantine from March 2020 through May 25, 2020, and our employees are not represented by labor unions. We consider our relationship with our employees to be positive.

 

ITEM 1A. Risk Factors

 

The following important factors, and the important factors described elsewhere in this report or in our other filings with the SEC, could affect (and in some cases have affected) our results and could cause our results to be materially different from estimates or expectations. Other risks and uncertainties may also affect our results or operations adversely. The following and these other risks could materially and adversely affect our business, operations, results or financial condition.

 

Risks Relating to our Business

 

Limited Operating History

 

We are an early-stage company that has generated minimal revenues and we have a limited operating history upon which our business and future prospects may be evaluated. We are subject to all of the business risks and uncertainties associated with any new business enterprise in the cannabis industry, including the risk that we will not achieve our operating goals. In order for us to meet future operating requirements, we will need to successfully grow, harvest and/or sell our cannabis products. Until such time as we are able to fund our business from operations, we will be required to raise funds through various sources, including the sale of equity and debt securities, Failure to generate cash from operations and to reach profitability may adversely affect our success.

 

We have had a history of losses, we expect losses in the future, and there can be no assurance that we will become profitable in the future.

 

We have experienced operating losses on an ongoing basis. For the years ended December 31, 2023 and 2022, we incurred net losses of $3,953,321 and $3,059,477, respectively. As of such dates, we had accumulated deficits of $26,929,686 and $22,976,365, respectively. We expect our losses to continue for the foreseeable future. These continuing losses may be greater than current levels. If our revenues do not increase substantially or if our expenses exceed our expectations, we may never become profitable. Even if we do achieve profitability, we may not sustain profitability on a quarterly or annual basis in the future.

 

Our auditor has given us a “going concern” qualification, which questions our ability to continue as a going concern without additional financing.

 

Our independent certified public accountant has added an emphasis paragraph to its report on our financial statements for the year ended December 31, 2023 regarding our ability to continue as a going concern. Key to this determination is our recurring net losses, an accumulated deficit, and a working capital deficiency. In the event sales do not materialize at expected levels, management would seek additional financing or would conserve cash by further reducing expenses. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations or cause substantial dilution for our stockholders. If we are unable to obtain additional funds, our ability to carry out and implement our planned business objectives and strategies will be significantly delayed, limited or may not occur. We cannot guarantee that we will become profitable.

 

Our Wholly-owned Colombian Subsidiary, OWP SAS, is Operating under Court Supervision Pursuant to a Reorganization Proceeding

 

OWP SAS experienced significant operational and managerial challenges over the past several years, resulting in the accumulation of financial obligations of approximately $1.2 million, which are substantially past due. OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia on December 22, 2023. There are many risks attendant to the Reorganization Proceeding, including OWP SAS’s ability to obtain approval from the court to conduct its normal business operations, maintain its cannabis licenses, satisfy its financial obligations to its creditors, the availability of operating capital during the pendency of its Restructuring Proceeding, the length of time that the Company will operate in the Reorganization Proceedings and the possibility that it may be unable to obtain any additional funding. Failure to achieve any of these objectives could have a material adverse effect on the business of the Company and OWP SAS.

 

7

 

 

Change of Cannabis Laws, Regulations and Guidelines

 

Cannabis laws and regulations in Colombia and other jurisdictions where we intend to transact business are dynamic and subject to evolving interpretations which could require us to incur substantial costs associated with compliance or alter certain aspects of our business plan. Regulations may be enacted in the future that will be directly applicable to certain aspects of our cultivation, manufacturing and exporting businesses for our cannabis and hemp related products. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. Management expects that the legislative and regulatory environment in the cannabis industry in Colombia and internationally will continue to be dynamic and will require innovative solutions to comply with this changing legal landscape in this nascent industry for the foreseeable future. Compliance with any such legislation may have a material adverse effect on our business, financial condition and results of operations.

 

Public opinion can also exert a significant influence over the regulation of the cannabis industry. A negative shift in the public’s perception of the cannabis industry could affect future legislation or regulation in different jurisdictions.

 

Reliance on Colombian Licenses, Authorizations and Quotas

 

Our ability to import seeds, grow, manufacture, distribute and sell cannabis and hemp in Colombia or internationally is dependent on our ability to sustain and/or obtain the necessary licenses and authorizations by certain authorities in Colombia and/or the importing jurisdiction. The licenses and authorizations are subject to ongoing compliance and reporting requirements and our ability to obtain, sustain or renew any such licenses and authorizations on acceptable terms is subject to changes in regulations and policies and to the discretion of the applicable authorities or other governmental agencies in foreign jurisdictions. Failure to comply with the requirements of the licenses or authorizations or any failure to maintain the licenses or authorizations would have a material adverse impact on our business, financial condition and operating results. In addition, Colombian regulators limit the cultivation and sale of psychoactive cannabis by quotas issued on an annual basis to licensed producers.

 

Although we believe that we will meet the requirements to obtain, sustain or renew the necessary licenses and authorizations, there can be no guarantee that the applicable authorities will issue these licenses or authorizations. In addition, to date we have not been issued quotas from Colombian regulatory authorities that would allow us to commence the commercial sale of psychoactive cannabis products in Colombia. Should the authorities fail to issue the necessary licenses or authorizations, including required quotas, we may be curtailed or prohibited from the production and/or distribution of cannabis and hemp or from proceeding with the development of our operations as currently proposed and our business, financial condition and results of the operation may be materially adversely affected.

 

Regulatory Compliance Risks

 

Achievement of our business objectives of becoming a producer of raw cannabis and hemp related products is contingent, in part, upon compliance with regulatory requirements enacted by applicable governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of our products in Colombia and other jurisdictions where we intend to distribute and sell our products. We will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. Civil or criminal fines or penalties may be imposed on us for violations of applicable laws or regulations. Vigorous enforcement of these laws could require extensive changes to our operations, increase our compliance costs or give rise to material liabilities, which could have a material adverse effect on our business, results of operations and financial condition.

 

Competition

 

There are many companies engaged in the cannabis business who we will compete with, including larger and more established companies with substantially greater marketing, financial, human and other resources than we have. These companies include PharmaCielo, CannaVida, Empresa Colombiana de Cannabis, Khiron Life Sciences Corp., MedCan, Canopy Growth Corporation, and Clever Leaves. Although we believe we are competitively positioned to be a leader in the medicinal cannabis industry given our early entry into the market, the management team’s expertise in medical product branding, marketing, quality control, and market relationships, competition in the medical cannabis industry is growing quickly. As more competitors enter the market, prices may be reduced. We believe our approach in creating brand loyalty will allow us to effectively compete in the market but there is no assurance that will be the case, and our competitors may adopt a similar or identical approach. To date, we have obtained four licenses in Colombia that authorize us to engage in cannabis activities, and there are currently few authorized Colombian producers. However, Colombia offers an open process to apply for licenses and there are no significant barriers to entry. As a result, our ability to generate revenues and earnings may be reduced as competition intensifies, thereby causing a material adverse effect on our business and financial condition.

 

8

 

 

Ability to Establish and Maintain Bank Accounts

 

Many banking institutions in countries where we or our prospective customers operate will not accept payments related to the cannabis industry due to domestic laws and regulations or pressure exerted by the United States on banks with laws subject to the laws of the United States (including, the Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act)). Failure to conduct our business through normal banking channels may impede our ability to make payments for goods and services and transact business in the ordinary course. Failure to operate in normal banking channels may also increase our cost of doing business and adversely impact our business. In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that we may be required to seek alternative payment solutions. If the industry was to move toward alternative payment solutions, we would have to adopt policies and protocols to manage the Company’s exposure to foreign exchange and interest rate risks. Our inability to effectively manage such risks may adversely affect our operations and financial performance.

 

Anti-Money Laundering Laws and Regulations

 

We are subject to a variety of laws and regulations within Colombia and internationally that are designed to prevent money laundering and proceeds of crime through strict financial recordkeeping. In the event that any of our investments, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such investments are found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under applicable legislation. Money laundering laws could restrict or otherwise jeopardize our ability to declare or pay dividends, effect other distributions or subsequently cause the repatriation of such funds to the United States or to any shareholders’ jurisdiction of residence. Furthermore, while we have no current intention to declare or pay dividends on our common stock in the foreseeable future, in the event that a determination was made that the revenues from our cannabis operations could reasonably be shown to constitute proceeds of crime, we may decide or be required to suspend the declaration, and or, payment of dividends without advance notice and for an extended or indefinite period of time.

 

Foreign Trade Policies

 

Our international operations are subject to inherent risks, including changes in the regulations governing the flow of cannabis products between countries, fluctuations in cross-currency rates, discriminatory fiscal policies, unexpected changes in local regulations and laws and the uncertainty of enforcement of remedies in foreign jurisdictions. In addition, foreign jurisdictions could impose tariffs, quotas, trade barriers and other similar restrictions on our international sales and subsidize competing cannabis products. All of these risks could result in increased costs or a reduction in revenues.

 

United States Regulation

 

Although we do not believe that our limited U.S. activity will subject us to regulation under U.S. federal or state laws applicable to the sale of cannabis and marijuana products, we cannot assure you that current or future U.S. laws and regulations will not detrimentally affect our business. Local, state and federal cannabis laws and regulations in the United States are constantly changing and they are subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our product or service offerings. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our revenues, profitability, and financial condition. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.

 

Liability, Enforcement, Complaints, etc.

 

Our participation in the cannabis and hemp industries may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by third parties, other companies and/or various governmental authorities against us. Litigation, complaints, and enforcement actions involving us could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on our future cash flows, earnings, results of operations and financial condition.

 

9

 

 

Legal Proceedings

 

From time to time, we may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom we transact business and other proceedings arising in the ordinary course of business. We will evaluate our exposure to these legal and regulatory proceedings and establish reserves for the estimated liabilities in accordance with generally accepted accounting principles. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on our financial results.

 

Environmental Regulations

 

We are subject to Colombian environmental laws governing the use of natural resources, which prohibit such use that causes harm to the interests of the community or of third parties. Parties that cause environmental damage while acting under the authority of a permit and, or license, are responsible for incurring the costs to rectify the damage. The imposition of environmental sanctions in addition to civil and criminal penalties may be imposed. Environmental damage caused while a party is acting without a license may lead to the imposition of sanctions, in addition to civil or criminal proceedings. Parties that cause environmental damage, in addition to sanctions or penalties that apply, are also required to carry out studies to assess the characteristics of the damage. Colombian environmental authorities may investigate potential claims, authorize preventative measures, or impose sanctions on parties breaching environmental law. Any such measures imposed on us could have a material adverse effect on our business.

 

Demand for Cannabis and Derivate Products

 

The global sale of cannabis and hemp products is a new industry as a result of recent legal and regulatory changes. Although we expect demand for licensed cannabis to exceed supply produced by licensed producers, there is a risk that such demand does not develop as anticipated. Further, there is a risk that the adoption rate by pharmacies to sell medical cannabis is lower than expected or that such adoption rate may take longer than anticipated. There is also a risk that the international export market for medicinal cannabis and extracts, such as CBD, CBG and CBC, will not materialize as projected or not be commercially viable. Should any of such events materialize, the result may have a material adverse effect on our business, operations and financial condition.

 

Weather, Climate Change and Risks Inherent in an Agricultural Business

 

Our business involves growing and/or sourcing cannabis and related products, which is an agricultural product. Although our medical cannabis is intended to be grown in greenhouses, hemp used as feedstock for medicinal extracts and derivatives will be grown both outdoors and in greenhouses. The occurrence of severe adverse weather conditions, especially droughts, hail, floods or frost, is unpredictable and may have a potentially devastating impact on agricultural production and may otherwise adversely affect the supply of cannabis and hemp. Adverse weather conditions may be exacerbated by the effects of climate change and may result in the introduction and increased frequency of pests and diseases. The effects of severe adverse weather conditions may reduce our yields or require us to increase our level of investment to maintain yields. Additionally, higher than average temperatures and rainfall can contribute to an increased presence of insects and pests, which could negatively affect cannabis crops. Future droughts could reduce the yield and quality of our cannabis production, which could materially and adversely affect our business, financial condition and results of operations.

 

The occurrence and effects of plant disease, insects and pests can be unpredictable and devastating to agriculture, potentially rendering all or a substantial portion of the affected harvests unsuitable for sale. Even if only a portion of the crop and, or, production is damaged, our results of operations could be adversely affected as all or a substantial portion of the production costs may have been incurred. Although some plant diseases are treatable, the cost of treatment can be high and such events could adversely affect our operating results and financial condition. Furthermore, if we fail to control a given plant disease and the production is threatened, we may be unable to supply our customers, which could adversely affect our business, financial condition and results of operations. There can be no assurance that natural elements will not have a material adverse effect on any such production.

 

Product Liability

 

As a manufacturer, distributor and/or seller of cannabis products designed to be ingested or inhaled by humans, we face an inherent risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused damages, loss or injury. In addition, the sale of our cannabis products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of our cannabis products alone or in combination with other medications or substances could occur. We may be subject to various product liability claims, including, among others, that our products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. A product liability claim or regulatory action against us could result in increased costs, could adversely affect our reputation with our clients and consumers generally, and could have a material adverse effect on our results of operations and financial condition. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all.

 

10

 

 

Energy Prices and Supply

 

We may require substantial amounts of diesel and electric energy and other resources to harvest and transport cannabis and hemp. We rely upon third parties for our supply of energy resources used in our operations. The prices for and availability of energy resources may be subject to change or curtailment, respectively, due to, among other things, new laws or regulations, imposition of new taxes or tariffs, interruptions in production by suppliers, imposition of restrictions on energy supply by government, worldwide price levels and market conditions. If our energy supply is curtailed for an extended period of time and we are unable to find replacement sources at comparable prices, or at all, our business, financial condition and results of operations would be materially and adversely affected.

 

Retention and Acquisition of Skilled Personnel

 

We will be required to attract and retain top quality talent to compete in the marketplace. We believe our future growth and success will depend in part on our abilities to attract and retain highly skilled managerial, product development, sales and marketing, and finance personnel. There can be no assurance of success in attracting and retaining such personnel. Shortages in qualified personnel could limit our ability to be successful. At present and for the near future, we will depend upon a relatively small number of employees primarily in Colombia to develop, manufacture, market, sell and distribute our products. As the size of our business increases, we will seek to hire additional employees in other jurisdictions. Expansion of marketing and distribution of our products will require us to find, hire and retain additional capable employees who can understand, explain, market and sell our products and/or our ability to enter into satisfactory logistic arrangements to sell our products. There is intense competition for capable personnel in all of these areas and we may not be successful in attracting, training, integrating, motivating, or retaining new personnel or subcontractors for these required functions.

 

Emerging Market Risks

 

Emerging market investment generally poses a greater degree of risk than investment in more mature market economies as developing market economies are more susceptible to destabilization resulting from domestic and international developments.

 

Colombia’s legal and regulatory requirements in connection with companies conducting agricultural activities, banking system and controls as well as local business culture and practices are different from those in the United States. Our officers and directors must rely, to a great extent, on our local legal counsel and local consultants retained by us in order to keep abreast of material legal, regulatory and governmental developments as they pertain to and affect our business operations, and to assist us with our governmental relations. We also rely on the advice of local experts and professionals in connection with current and new regulations that develop in respect of banking, financing and tax matters. Any developments or changes in such legal, regulatory or governmental requirements or in local business practices are beyond our control and may adversely affect our business.

 

We also bear the risk that changes can occur to the Government in Colombia and a new government may void or change the laws and regulations that we are relying upon. Currently, there are no restrictions on the repatriation from Colombia of earnings to foreign entities and Colombia has never imposed such restrictions. However, there can be no assurance that restrictions on repatriation of earnings will not be imposed in the future. Exchange control regulations for Colombia require that any proceeds in foreign currency originated on exports of goods from Colombia be repatriated to Colombia. However, purchase of foreign currency is allowed through Colombian authorized financial entities for purposes of payments to foreign suppliers, repayment of foreign debt, payment of dividends to foreign stockholders and other foreign expenses.

 

Due to our location in Colombia, our business, financial position and results of operations may be affected by the general conditions of the Colombian economy, price instabilities, currency fluctuations, inflation, interest rates, regulatory changes, taxation changes, social instabilities, political unrest and other developments in or affecting Colombia, over which we do not have control.

 

Risks Related to Conducting Operations in Colombia

 

We were recently granted medicinal cannabis licenses in Colombia. Over the past 10 to 15 years, the Government of Colombia has made strides in improving the social, political, economic, legal and fiscal regimes. However, operations in Colombia remain subject to risk due to the potential for social, political, economic, legal and fiscal instability. The Government of Colombia faces ongoing problems including, but not limited to, unemployment and inequitable income distribution and unstable neighboring countries. The instability in neighboring countries could result in an influx of immigrants resulting in a humanitarian crisis and/or increased illegal activities. Colombia is also home to a number of insurgency groups and large swaths of the countryside are under guerrilla influence. In addition, Colombia experiences narcotics-related violence, a prevalence of kidnapping, extortion and thefts and civil unrest in certain areas of the country. Such instability may require us to suspend operations on our properties.

 

11

 

 

Other risks exist relating to the conduct of business in Colombia. These risks include the future imposition of special taxes or similar charges, as well as foreign exchange fluctuations and currency convertibility and controls. Other risks of doing business in Colombia include our ability to enforce our contractual rights or the taking or nationalization of property without fair compensation, restrictions on the use of expatriates in our operations, renegotiation or nullification of existing concessions, licenses, permits and contracts, changes in taxation policies, or other matters.

 

The Government of Colombia recently reached a peace accord with the country’s largest guerrilla group. The Government of Colombia also entered into and dissolved formal discussions with the country’s second largest guerrilla group due to their unwillingness to cease criminal and violent crimes. There is no certainty that the agreements will be adhered to by all of the members of the guerrilla groups or that a peace agreement will be ultimately reached with the country’s second largest guerrilla group. There is a risk that any peace agreement might contain new laws or change existing laws that could have a material adverse effect on us. Furthermore, the achievement of peace with the country’s guerrilla groups could create additional social or political instability in the immediate aftermath, which could have a material adverse effect on our operations.

 

Global Economy

 

Financial and commodity markets in Colombia are influenced by the economic and market conditions in other countries, including other South American and emerging market countries and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Colombia, investors’ reactions to developments in these other countries, such as the recent developments in the global financial markets, may substantially affect the capital flows into, and the market value of securities of issuers with operations in Colombia.

 

Insurance Coverage

 

Our production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, plant diseases and pest infestations, other natural phenomena, industrial accidents, labor disputes, changes in the legal and regulatory framework applicable to us, and environmental contingencies. We will endeavor to obtain appropriate insurance covering these risks in amounts sufficient to support a downturn in the sale of our products due to these potential production risks. The cost of such insurance may be high and we may not be able to obtain sufficient amount of insurance to cover these risks.

 

Operations in Spanish

 

As a result of our conducting most of our operations in Colombia, our regulatory licenses and books and records, including key documents such as material contracts and financial documentation, are principally negotiated and entered into in the Spanish language and English translations may not exist or be readily available.

 

General Business Risks

 

Inability to Manage Growth

 

We may not be able to effectively manage our growth as a producer, manufacturer and exporter of cannabis and hemp products. Our strategy envisions growing our business. We plan to expand our production and manufacturing capability and create a global distribution network. Any growth in or expansion of our business is likely to continue to place a strain on our management and administrative resources, infrastructure and systems. As with other growing businesses, we expect that we will need to further refine and expand our business development capabilities, our systems and processes and our access to financing sources. We also will need to hire, train, supervise and manage new employees. These processes are time consuming and expensive, will increase management responsibilities and will divert management attention. We cannot assure you that we will be able to:

 

  cultivate and/or source cannabis material in Colombia and expand our manufacturing processes and systems in our facilities in Colombia;
  execute and perform under our current manufacturing and distribution agreements with Smokiez Edibles and Kx Family Care;
  raise additional capital to fund our operations;
  identify and hire qualified employees or retain valued employees; or
  obtain and maintain necessary licenses in relevant jurisdictions

 

Our inability, or failure to effectively manage, our growth and expansion could harm our business and materially and adversely affect our operating results and financial condition.

 

12

 

 

Speculative Forecasts

 

Any forecasts we provide will be highly speculative in nature and we cannot predict results in a development stage company with a high degree of accuracy. Any financial projections, especially those based on ventures with minimal operating history, are inherently subject to a high degree of uncertainty, and their ultimate achievement depends on the timing and occurrence of a complex series of future events, both internal and external to the enterprise. There can be no assurance that potential revenues or expenses we project will be accurate.

 

Limited Management Team

 

Our limited senior management team size may hamper our ability to effectively manage a publicly traded company while operating our business. Our management team has experience in the management of publicly traded companies and complying with federal securities laws, including compliance with recently adopted disclosure requirements on a timely basis. They realize it will take significant resources to meet these requirements while simultaneously working on cultivating, developing and distributing our cannabis and hemp related products. Our management will be required to design and implement appropriate programs and policies in responding to increased legal, regulatory compliance and reporting requirements, and any failure to do so could lead to the imposition of fines and penalties and harm our business.

 

Risks Related to our Common Stock

 

Limited Trading

 

Although prices for shares of our common stock are quoted on the OTCQB tier of the OTC Markets, there is limited trading and no assurance can be given that an active public trading market will develop or, if developed, that it will be sustained. The OTC Markets is generally regarded as a less efficient and less prestigious trading market than other national markets. There is no assurance if or when our common stock will be quoted on another more prestigious exchange or market. The market price of our common stock is may be volatile as there will likely be a limited trading market for the stock, which may cause transactions of small blocks of stock to have a disproportionate impact on the stock price.

 

We may issue additional stock without stockholder consent.

 

Our Board of Directors has authority, without action or vote of the stockholders, to issue all or part of our authorized but unissued shares. Additional shares may be issued in connection with future financing, acquisitions, employee stock plans, or otherwise. Any such issuance will dilute the percentage ownership of existing stockholders. The Board of Directors can also issue preferred stock in one or more series and fix the terms of such stock without stockholder approval. Preferred stock may include the right to vote as a series on particular matters, preferences as to dividends and liquidation, conversion and redemption rights and sinking fund provisions. The issuance of preferred stock could adversely affect the rights of the holders of common stock and reduce the value of the common stock. In addition, specific rights granted to holders of preferred stock could discourage, delay or prevent a transaction involving a change in control of our company, even if doing so would benefit our stockholders. Such issuance could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing and to cause us to take other corporate actions you desire.

 

13

 

 

Broker-dealers may be discouraged from effecting transactions in our common stock because it is considered a penny stock and is subject to the penny stock rules.

 

Our common stock currently constitutes “penny stock.” Subject to certain exceptions, for the purposes relevant to us, “penny stock” includes any equity security that has a market price of less than $5.00 per share. Rules 15g-1 through 15g-9 promulgated under the Securities Exchange Act of 1934, as amended, impose sales practice and disclosure requirements on certain brokers-dealers who engage in certain transactions involving a “penny stock.” In particular, a broker-dealer selling penny stock to anyone other than an established customer or “accredited investor” (generally, an individual with net worth in excess of $1,000,000 or an annual income exceeding $200,000, or $300,000 together with his or her spouse), must make a special suitability determination for the purchaser and must receive the purchaser’s written consent to the transaction prior to sale, unless the broker-dealer or the transaction is otherwise exempt. In addition, the penny stock regulations require the broker-dealer to deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt. A broker-dealer is also required to disclose commissions payable to the broker-dealer and the registered representative and current quotations for the securities. Finally, a broker-dealer is required to send monthly statements disclosing recent price information with respect to the penny stock held in a customer’s account and information with respect to the limited market in penny stocks.

 

The additional sales practice and disclosure requirements imposed upon broker-dealers may discourage broker-dealers from effecting transactions in our shares, which could severely limit the market liquidity of the shares and impede the sale of our shares in the secondary market.

 

Because our Board of Directors does not intend to pay dividends on our common stock in the foreseeable future, stockholders may have to sell their shares of our common stock to realize a return on their investment in the company.

 

Holders of our common stock are entitled to receive dividends if, and when, declared by our Board of Directors out of funds legally available. To date, we have paid no dividends. Our Board of Directors does not intend to declare any dividends in the foreseeable future, but instead intends to retain all earnings, if any, for use in our business operations. Accordingly, a return on an investment in shares of our common stock may be realized only through a sale of such shares, if at all.

 

Control of Common Stock will Influence Decision Making

 

Our officers, directors and principal stockholders are able to exert significant influence over us and may make decisions that are not in the best interests of all stockholders. Our officers, directors and principal stockholders (greater than 5% stockholders) collectively own approximately 87.0% of our fully-diluted common stock. As a result of such ownership, these stockholders are able to affect the outcome of, or exert significant influence over, all matters requiring stockholder approval, including the election and removal of directors and any change in control. In particular, this concentration of ownership of our common stock could have the effect of delaying or preventing a change of control of our company or otherwise discouraging or preventing a potential acquirer from attempting to obtain control of our company. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our stockholders from realizing a premium over the market prices for their shares of our common stock.

 

We are an Emerging Growth Company Within the Meaning of the Securities Act.

 

We are an “emerging growth company” within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700 million as of the end of any second quarter of a fiscal year, in which case we would no longer be an emerging growth company as of the end of such fiscal year. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.

 

14

 

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.

 

Antitakeover Protections

 

Anti-takeover provisions may limit the ability of another party to acquire us, which could cause our stock price to decline. Our articles of incorporation, as amended, bylaws and Nevada law contain provisions that could discourage, delay or prevent a third party from acquiring us, even if doing so may be beneficial to our stockholders. In addition, these provisions could limit the price investors would be willing to pay in the future for shares of our common stock.

 

Increased Compliance Costs

 

The requirements of being a public company, including compliance with the reporting requirements of the Securities Exchange Act of 1934, as amended, and the requirements of the Sarbanes-Oxley Act of 2002, may strain our resources, increase our costs and distract management, and we may be unable to comply with these requirements in a timely or cost-effective manner. As a public company, we need to comply with laws, regulations and requirements, certain corporate governance provisions of the Sarbanes-Oxley Act of 2002, related regulations of the SEC, and requirements of the principal trading market upon which our common stock may trade, with which we are not required to comply as a private company. As a result, the combined business will incur significant legal, accounting and other expenses that a private company would not incur. Complying with these statutes, regulations and requirements will occupy a significant amount of the time of our board of directors and management, will require us to have additional finance and accounting staff, may make it more difficult to attract and retain qualified officers and members of our board of directors, particularly to serve on the audit committee, and may make some activities more difficult, time consuming and costly. We will need to:

 

  institute a more comprehensive compliance function;
  establish new internal policies, such as those relating to disclosure controls and procedures and insider trading;
  design, establish, evaluate and maintain a system of internal control over financial reporting in compliance with the requirements of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC and the Public Company Accounting Oversight Board;
  prepare and distribute periodic reports in compliance with its obligations under the federal securities laws including the Securities Exchange Act of 1934, as amended, or Exchange Act;
  involve and retain to a greater degree outside counsel and accountants in the above activities; and
  establish an investor relations function.

 

If we are unable to accomplish these objectives in a timely and effective fashion for our business, our ability to comply with financial reporting requirements and other rules that apply to reporting companies could be impaired. If our finance and accounting personnel insufficiently support our business in fulfilling these public-company compliance obligations, or if we are unable to hire adequate finance and accounting personnel, we could face significant legal liability, which could have a material adverse effect on our financial condition and results of operations. Furthermore, if we identify any issues in complying with those requirements (for example, if our company or the independent registered public accountants identified a material weakness or significant deficiency in our company’s internal control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely affect, our reputation or investor perceptions of our company.

 

Risks Relating to Our Agreements with Tysadco Partners, LLC

 

The sale of our common stock to Tysadco may cause dilution, and the sale of the shares of common stock acquired by Tysadco, or the perception that such sales may occur, could cause the price of our common stock to fall.

 

Pursuant to a Purchase Agreement, Tysadco has committed to purchase up to an aggregate of $10,000,000 of our common stock. The shares that may be sold pursuant to the Purchase Agreement in the future may be sold by us to Tysadco at our discretion from time to time, commencing three years from February 9, 2024, the date the SEC declared the registration statement effective. The per share purchase price for the shares that we may sell to Tysadco under the Purchase Agreement will fluctuate based on the price of our common stock, and will be equal to 88% of the of the lowest daily volume weighted average price of our common stock during the period of 10 trading days beginning five trading days preceding the day we deliver the applicable put notice to Tysadco. Depending on market liquidity at the time, sales of shares of common stock to Tysadco may cause the trading price of our common stock to fall.

 

15

 

 

We generally have the right to control the timing and amount of any sales of our shares to Tysadco, except that, pursuant to the Purchase Agreement, we may not sell shares to Tysadco if the sale would result in its beneficial ownership of more than 4.99% of our outstanding common stock. Tysadco may ultimately purchase all, some or none of the shares of our common stock that may be sold pursuant to the Purchase Agreement and, after it has acquired shares, Tysadco may sell all, some or none of those shares. Therefore, sales to Tysadco by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Tysadco, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

 

Tysadco will pay less than the then-prevailing market price for our common stock for purchases under the Purchase Agreement.

 

The common stock to be issued to Tysadco pursuant to the Purchase Agreement will be purchased at a 12% discount to the lowest volume weighted average price of our common stock during the during the period of 10 trading days beginning five trading days preceding the day we deliver the applicable put notice to Tysadco. Tysadco has a financial incentive to sell our common stock immediately upon receiving the shares to realize the profit equal to the difference between the discounted price and the market price. If Tysadco sells the shares, the price of our common stock could decrease. If our stock price decreases, Tysadco may have a further incentive to sell the shares of our common stock that it holds. These sales may have a further impact on our stock price.

 

We may not be able to put to Tysadco all $10,000,000 of shares available under the Purchase Agreement.

 

The Purchase Agreement provides for the purchase by Tysadco of up to $10,000,000 of shares of our common stock. Our ability to draw down funds and sell shares under the Purchase Agreement requires the satisfaction of a number of conditions, including that the registration statement of which this prospectus is a part be declared effective by the SEC and continue to be effective at the time of the put, as well as Tysadco’s compliance with its obligations under the Purchase Agreement. Accordingly, there can be no guarantee that we will be able to draw down all or any portion of the $10,000,000 available to us under the Purchase Agreement.

 

ITEM 1B. Unresolved Staff Comments

 

Not Applicable.

 

ITEM 1C. CYBERSECURITY

 

Risk Management and Strategy

 

We periodically assess risks from cybersecurity threats, and monitor our information systems for potential vulnerabilities. However, to date, given the small size of our company and the nature of our operations, our reliance on information systems has been limited to the use of standard off-the-shelf software (such as Google, QuickBooks and Microsoft Office) and the use by our employees of standard personal computers. Accordingly, management has not implemented any formal process for assessing, identifying, and managing risks from cybersecurity threats.

 

Risks from cybersecurity threats have, to date, not materially affected us, our business strategy, results of operations or financial condition. We discuss how cybersecurity incidents could materially affect us in our risk factor disclosures in Item 1A of this Annual Report on Form 10-K.

 

Governance

 

As discussed above, given the nature of our current operations and our experience to date, we do not currently perceive cybersecurity as a particularly significant risk to our business. Accordingly, we have not tasked our Board of Directors with any additional cybersecurity oversight duties, or designated any committee of the Board of Directors to specifically oversee cybersecurity risks to our business.

 

ITEM 2. Properties

 

Our principal executive offices are located at 6605 Grand Montecito Pkwy., Suite 100, Las Vegas, NV 89149, Telephone No.: (800) 605-3210. Our leased premises are shared and are utilized for corporate business offices. Our Nevada premises are subject to a month-to-month lease agreement.

 

We believe that our current facilities are adequate for our current needs. We intend to secure new facilities or expand existing facilities as necessary to support future growth. We believe that suitable additional space will be available on commercially reasonable terms as needed to accommodate our operations.

 

ITEM 3. Legal Proceedings

 

Due to challenging economic conditions, OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia on December 22, 2023. As of December 31, 2023, OWP SAS is involved in a total of 23 separate lawsuits for various civil and labor disputes in the municipal civil courts in Colombia, in the Cities of Bogota, Cali. Funza and Popayán. If the civil courts rule against OWP SAS, we estimate the potential liability from these claims is approximately $310,000. However, this is only an estimate, and our potential liability could be greater.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

16

 

 

PART II

 

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

There is a limited public market for our common stock. Shares of our common stock trade on the over-the-counter market and are quoted on the OTCQB tier of the OTC Markets under the symbol “OWPC”.

 

The following table sets forth, for the fiscal quarters indicated, the high and low bid information for our common stock, as reported on the OTC Markets. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

 

   High   Low 
Fiscal Year Ended December 31, 2023          
First Quarter  $0.13   $0.05 
Second Quarter  $0.10   $0.05 
Third Quarter  $0.12   $0.06 
Fourth Quarter  $0.10   $0.02 
           
Fiscal Year Ended December 31, 2022          
First Quarter  $0.14   $0.08 
Second Quarter  $0.24   $0.07 
Third Quarter  $0.19   $0.09 
Fourth Quarter  $0.13   $0.07 

 

As of May 13, 2024, there were approximately 77 shareholders of record of our common stock. Such number does not include any shareholders holding shares in nominee or “street name”. As of May 13, 2024, there were 104,329,919 shares of common stock outstanding on record.

 

Dividends

 

We have not declared or paid any dividends on our common stock since our inception and do not anticipate paying dividends for the foreseeable future. The payment of dividends is subject to the discretion of our board of directors and depends, among other things, upon our earnings, our capital requirements, our financial condition, and other relevant factors. We intend to reinvest any earnings in the development and expansion of our business. Any cash dividends in the future to common shareholders will be payable when, as and if declared by our board of directors, based upon the board’s assessment of our financial condition and performance, earnings, need for funds, capital requirements, prior claims of preferred stock to the extent issued and outstanding, and other factors, including income tax consequences, restrictions and applicable laws. There can be no assurance, therefore, that any dividends on our common stock will ever be paid.

 

17

 

 

Equity Compensation Plan Information

 

This following table provides information about shares our common stock that may be issued under our options outstanding at December 31, 2023. Other than individual options outstanding reflected in the table below, we did not have any shares authorized for issuance under equity plans at December 31, 2023.

 

Plan category 

Number of securities

to be issued

upon exercise of

outstanding options,

warrants and rights

  

Weighted-average

exercise price of

outstanding options,

warrants and rights

  

Number of securities

remaining available

for future issuance

under equity

compensation plans

(excluding securities

reflected in column (a))

 
   (a)   (b)   (c) 
Equity compensation plans approved by security holders   5,392,000   $              0.15    4,608,000 
Equity compensation plans not approved by security holders (1)   19,511,650    0.24    N/A 
Total   21,753,650   $0.23    5,258,000 

 

(1) Represents options to purchase 5,500,000 shares of common stock at a per share exercise price of $0.13 issued outside of our option plan to our CEO, Isiah L. Thomas, III, and warrants to purchase a total of 12,011,650 and 2,000,000 shares of common stock at $0.25 and $0.50 per share, respectively.

 

On February 12, 2020, the Company’s stockholders approved our 2019 Stock Incentive Plan (the “2019 Plan”), which had been adopted by the Company’s Board of Directors (the “Board”) as of December 10, 2019. The 2019 Plan provides for the issuance of up to 10,000,000 shares of common stock to the Company and its subsidiaries’ employees, officers, directors, consultants and advisors, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted stock units (“RSUs”) and other performance stock awards. Options granted under the 2019 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. Unless sooner terminated in accordance with its terms, the Stock Plan will terminate on December 10, 2029.

 

Recent Sales of Unregistered Securities

 

Common Stock Issued for Series B Preferred Stock Conversions

 

On November 16, 2023, a shareholder converted 10,000 shares of Series B Preferred Stock into 1,000,000 shares of common stock, restricted in accordance with Rule 144, to Tysadco Partners, LLC.

 

Common Stock Sales

 

On October 2, 2023, the Company sold 1,000,000 shares of common stock, restricted in accordance with Rule 144, to an accredited investor for proceeds of $100,000.

 

Common Stock Issued as Consideration on Debt Financing

 

On December 7, 2023, the Company issued 269,261, restricted in accordance with Rule 144, to AJB Capital as consideration on debt financing.

 

Common Stock Issued for Services

 

On November 21, 2023, the Company issued 250,000 shares of common stock, restricted in accordance with Rule 144, to a consultant for services provided.

 

On October 4, 2023, the Company issued 572,083 shares of common stock, restricted in accordance with Rule 144, to ClearThink Capital Partners, LLC, for services provided.

 

In connection with the above security issuances, we did not pay any underwriting discounts or commissions. None of the sales of securities described or referred to above was registered under the Securities Act. In making the sales without registration under the Securities Act, we relied upon one or more of the exemptions from registration contained in Section 4(2) of the Securities Act, and in Regulation D promulgated under the Securities Act. No general solicitation or advertising was used in connection with the sales.

 

ITEM 6. Selected Financial Data

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

18

 

 

ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This discussion summarizes the significant factors affecting the operating results, financial condition, liquidity and cash flows of the Company for the fiscal years ended December 31, 2023 and 2022. The discussion and analysis that follows should be read together with the section entitled “Forward Looking Statements” and our financial statements and the notes to the financial statements included elsewhere in this annual report on Form 10-K.

 

Except for historical information, the matters discussed in this section are forward looking statements that involve risks and uncertainties and are based upon judgments concerning various factors that are beyond the Company’s control. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report.

 

Overview

 

We plan to be a producer of and/or source raw and processed cannabis and hemp plant ingredients for both medical and industrial uses across the globe. The Company is a holding company and conducts its business in Colombia through OWP SAS, its wholly-owned subsidiary. OWP SAS has received licenses from the Colombian government to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes in the town of Esmeralda-Popayán, Cauca, Colombia.

 

We are in the process of acquiring another Colombian subsidiary within the Bogota free trade zone, which has all requisite licenses for the cultivation, production, distribution and export of cannabis and hemp infused products, and will serve as the Company’s primary base of operations in the Colombian market. Establishing operations within the free trade zone provides favorable import/export commercial terms and taxation, and will improve logistics and the overall operating efficiencies for the Company due to the close proximity of El Dorado International Airport and the commercial, economic and cultural center of the city of Bogota itself.

 

OWP SAS owns approximately 30 acres and has a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we entered into agreements with a local farming co-operative, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we harvested in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced.

 

We have generated revenues since the second quarter of 2020. Between August 2021 and March 2022, we made payments of approximately $1,400,000 for the purchase of a state-of-the-art distillation machine that cleared customs and is currently located in a warehouse near Bogota. We intend to build out an extraction and production facility in the Bogota free trade zone adjacent to El Dorado International Airport in Bogota after we execute a lease for this location. Once the extraction equipment is placed in service, we will be one of the few companies in Colombia to both hold licenses and possess the capability to extract high-quality CBD and THC oils.

 

Due to challenging economic conditions and under prior management, OWP SAS experienced significant operational and managerial challenges in 2022 and 2023, resulting its accumulation of financial obligations of approximately $1.2 million, which are substantially past due. Without adequate resources and in an effort to forestall the imposition of interest, late charges, fines and any court-mandated order(s) to cease operations, OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia on December 22, 2023. During the Reorganization Proceeding, management intends to satisfy OWP SAS’s continuing financial obligations through the negotiation and/or settlement with creditors and the Colombian governmental authorities. Subject to court approval, the Company intends to continue normal operations, which consists of providing cannabinoids in bulk for the domestic and international markets, including the raw material for our brands and affiliate companies. At this time, the Company cannot predict the length of time of the Reorganization Proceeding. The Company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings to include the petitioning entity, OWP SAS, as well as the Company’s non-operating shell entities, Agrobase, S.A.S. and Hope Colombia, S.A.S., given the lack of independently identifiable operations. The deconsolidation resulted in a loss on deconsolidation of foreign subsidiaries in the amount of $1,564,823 for the year ended December 31, 2023.

 

We expect to start exporting products in 2024, including CBD flower and distillate oil. Our product pipeline may include premium coffee certified by the Colombian National Coffee Federation infused with CBD, teas infused with CBD and a series of wellness products, including sports CBD energy drinks for optimum performance, CBD facial and body creams for anti-inflammatory and anti-aging use and white label commercial agreements with partners in Europe, USA, and Latin America. We recently entered into strategic partnerships with Smokiez Edibles in Colombia and Stephen Marley’s Kx Family Care. There can be no assurances that these strategic partnerships will generate revenues or be profitable for the Company.

 

19

 

 

Critical Accounting Policies

 

The establishment and consistent application of accounting policies is a vital component of accurately and fairly presenting our financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”), as well as ensuring compliance with applicable laws and regulations governing financial reporting. While there are rarely alternative methods or rules from which to select in establishing accounting and financial reporting policies, proper application often involves significant judgment regarding a given set of facts and circumstances and a complex series of decisions.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.

 

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2023:

 

    State of    
Name of Entity   Incorporation   Relationship
One World Products, Inc.(1)   Nevada   Parent
OWP Ventures, Inc.(2)   Delaware   Subsidiary
One World Pharma S.A.S.(3)(6)   Colombia   Subsidiary
Colombian Hope, S.A.S.(4)(6)   Colombia   Subsidiary
Agrobase, S.A.S.(5)(6)   Colombia   Subsidiary

 

(1) Holding company in the form of a corporation.
(2) Holding company in the form of a corporation and wholly-owned subsidiary of One World Products, Inc.
(3) Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogotá on July 18, 2017. Its headquarters are located in Bogotá.
(4) Wholly-owned subsidiary of OWP Ventures, Inc., acquired on November 19, 2019, located in Colombia and legally constituted as a simplified stock company. This company has yet to incur any substantive income or expenses.
(5) Wholly-owned subsidiary of OWP Ventures, Inc., formed on September 12, 2019, located in Colombia and legally constituted as a simplified stock company. This company has yet to incur any substantive income or expenses.
(6) Deconsolidated subsidiary post-petition for reorganization under Colombian Law 1116 of 2006 on December 22, 2023. The operations prior to December 22, 2023 have been included in the Consolidated Financial Statements for the Year Ended December 31, 2023, but the assets and liabilities of the subsidiaries have been deconsolidated and omitted from the Balance Sheet for the Year Ended December 31, 2023.

 

The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its production efforts are within Popayán, Colombia.

 

Foreign Currency Translation

 

The functional currency of the Company is Colombian Peso (“COP”). The Company has maintained its financial statements using the functional currency, and translated those financial statements to the US Dollar throughout this report. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.

 

20

 

 

Comprehensive Income

 

The Company has adopted ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company’s sales to date have primarily consisted of the sale of seeds. These sales include multi-element arrangements whereby the Company collects 50% of the sale upon delivery of the sales, and the remaining 50% upon the completion of the harvest, whether the seeds result in a successful crop, or not. In addition, the Company has a right of first refusal to purchase products resulting from the harvest.

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

 

Basic and Diluted Loss Per Share

 

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended December 31, 2023 and 2022, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

21

 

 

Results of Operations for the Years ended December 31, 2023 and 2022

 

The following table summarizes selected items from the statement of operations for the years ended December 31, 2023 and 2022.

 

   For the Years Ended     
   December 31,   Increase / 
   2023   2022   (Decrease) 
             
Revenues  $7,589   $125,662   $(118,073)
Cost of goods sold   173,122    300,757    (127,635)
Gross loss   (165,533)   (175,095)   (9,562)
                
Operating expenses:               
General and administrative   1,289,656    1,587,017    (297,361)
Professional fees   591,416    431,737    159,679 
Depreciation expense   34,266    42,287    (8,021)
Total operating expenses:   1,915,338    2,061,041    (145,703)
                
Operating loss   (2,080,871)   (2,236,136)   (155,265)
                
Total other expense   (1,872,450)   (823,341)   1,049,109 
                
Net loss  $(3,953,321)  $(3,059,477)  $(670,979)

 

Revenues

 

Revenues for the year ended December 31, 2023 were $7,589, compared to $125,662 during the year ended December 31, 2022, a decrease of $118,073, or 94%. Revenues decreased as we transitioned to new management at our operating facility.

 

Cost of Goods Sold

 

Cost of goods sold for the year ended December 31, 2023 were $173,122, compared to $300,757 during the year ended December 31, 2022, a decrease of $127,635, or 42%. Cost of goods sold consists primarily of labor, depreciation and maintenance on cultivation and production equipment, and supplies consumed in our operations. Our gross margins were approximately negative 2,181% for the year ended December 31, 2023, compared to negative 139% during the year ended December 31, 2022. Costs of goods sold decreased as we transitioned to new management at our operating facility.

 

General and Administrative Expenses

 

General and administrative expenses for the year ended December 31, 2023 were $1,289,656, compared to $1,587,017 for the year ended December 31, 2022, a decrease of $297,361, or 19%. General and administrative expenses decreased primarily due to decreased salaries and wages and lease expenses in Colombia over the comparative period, as we transitioned to new management. The expenses for the current period consisted primarily of compensation expenses, office rent, and travel costs, including $207,233 of stock-based compensation, which consisted $89,850 of common stock and $117,383 of stock options that were issued to our officers. The expenses for the prior period consisted primarily of compensation expenses, office rent, and travel costs, including $117,388 of stock-based compensation, which consisted entirely of expense related to stock options that were issued to our officers. Stock-based compensation increased by $89,845, or 77%, for the year ended December 31, 2023, compared to the year ended December 31, 2022.

 

Professional Fees

 

Professional fees for the year ended December 31, 2023 were $591,416, compared to $431,737 during the year ended 2022, an increase of $159,679, or 37%. Professional fees included non-cash stock-based compensation of $278,353, consisting of $243,987 of common stock and $34,366 of stock options expense, during the year ended December 31, 2023, compared to $47,232, consisting entirely of stock options expense, during the year ended December 31, 2022, an increase of $231,121, or 489%. Professional fees increased primarily due to increased stock-based compensation during the current period.

 

22

 

 

Depreciation Expense

 

We had $34,266 of depreciation expense for the year ended December 31, 2023, compared to $42,287 of depreciation expense for the year ended December 31, 2022, a decrease of $8,021, or 19%. Depreciation expense decreased due to the prior year disposal of office equipment.

 

Other Income (Expense)

 

Other expenses, on a net basis, for the year ended December 31, 2023 were $1,872,450, compared to other expenses, on a net basis, of $823,341 for the year ended December 31, 2022. Other expense during the year ended December 31, 2023 consisted of a loss on disposal of fixed assets of $3,290, a loss of $1,564,823 on the deconsolidation of our foreign subsidiaries, and $308,741 of interest expense, including $19,603 on shares of common stock issued as commitment fees to AJB Capital on debt financing arrangements, as partially offset by a gain of $4,397 on the early extinguishment of leases and $7 of interest income. Other expenses for the year ended December 31, 2022 consisted of a loss on disposal of fixed assets of $9,041, and $956,858 of interest expense, including $339,133 on shares of series B preferred stock and common stock issued as commitment fees to Tysadco Partners on debt financing arrangements, as partially offset by $1,000 of sublease income, a gain on early extinguishment of leases of $20,148, a gain on forgiveness of PPP loan of $121,372 and $38 of interest income.

 

Net Loss

 

Net loss for the year ended December 31, 2023 was $3,953,321, or $0.05 per share, compared to $3,059,477, or $0.05 per share, during the year ended December 31, 2022, an increase of $893,844, or 29%. The net loss for the year ended December 31, 2023 included non-cash expenses consisting of $34,266 of depreciation, a $3,290 loss on disposal of fixed assets, a loss of $1,564,823 on the deconsolidation of our foreign subsidiaries, $505,189 of stock-based compensation, and $308,741 of interest expense, including $55,539 on the amortization of debt discounts and $19,603 on shares of common stock issued as commitment fees to AJB Capital on debt financing arrangements. The net loss for the year ended December 31, 2022 included non-cash expenses consisting of $42,287 of depreciation, a $9,041 loss on disposal of fixed assets, $503,753 of stock-based compensation, and $956,858 of interest expense, including $412,673 on the amortization of debt discounts and $339,133 on shares of series B preferred stock and common stock issued as commitment fees to Tysadco Partners on debt financing arrangements.

 

Liquidity and Capital Resources

 

As of December 31, 2023, the Company had current assets of $13,882, consisting of cash of $726 and other current assets of $13,156. The Company’s current liabilities as of December 31, 2023 were $3,872,111, consisting of $528,645 of accounts payable, $939,368 of accrued expenses, $196,734 of dividends payable, a convertible note payable to a related party in the amount of $750,000, and $1,457,364 of debts, including $1,146,500 owed to related parties.

 

The following table summarizes our total current assets, liabilities and working capital at December 31, 2023 and 2022.

 

   December 31, 
   2023   2022 
Current Assets  $13,882   $123,467 
           
Current Liabilities  $3,872,111   $2,227,435 
           
Working Capital  $(3,858,229)  $(2,103,968)

 

23

 

 

The following table summarizes our cash flows during the years ended December 31, 2023 and 2022, respectively.

 

   For the Year Ended 
   December 31, 
   2023   2022 
Net cash used in operating activities  $(1,194,131)  $(1,380,483)
Net cash used in investing activities   (5,046)   (36,851)
Net cash provided by financing activities   1,059,500    1,317,581 
Effect of exchange rate changes on cash   131,046    (8,909)
Cash removed in deconsolidated foreign subsidiaries   (1,659)   - 
           
Net change in cash  $(10,290)  $(108,662)

 

The decrease in funds used in operating activities for the year ended December 31, 2023, compared to the year ended December 31, 2022, was primarily due to decreased operations in the current year as capital resources tightened.

 

The decrease in funds used in investing activities for the year ended December 31, 2023, compared to the year ended December 31, 2022, was due primarily to decreased purchases of fixed assets in the year ended December 31, 2023.

 

The decrease in funds provided by financing activities for the year ended December 31, 2023, compared to the year ended December 31, 2022, was due primarily to $558,081 of decreased net debt financing proceeds received, as partially offset by $300,000 of increased proceeds received from the sale of our securities during the year ended December 31, 2023.

 

Satisfaction of our Cash Obligations for the Next 12 Months

 

As of December 31, 2023, we had $726 of cash on hand and negative working capital of $3,858,229. On April 19, 2024, we raised approximately $1.47 million from the sale of convertible notes in the amount of $1.6 million to two accredited investors, which included the issuance of 2 million shares as a commitment fee to one investor and a pre-funded warrant to purchase 8,666,667 shares of our common stock to the other investor, of which approximately $620,000 was used to partially pay off outstanding debts. We do not currently have sufficient funds to fund our operations at their current levels for the next twelve months. As we implement our cannabis cultivation business and attempt to expand operational activities, we expect to continue to experience net negative cash flows from operations in amounts not now determinable, and will be required to obtain additional financing to fund operations. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to achieve sustainable revenues and profitable operations. Since inception, we have raised funds primarily through the sale of equity securities. We will need, and are currently seeking, additional funds to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations or cause substantial dilution for our stockholders. If we are unable to obtain additional funds, our ability to carry out and implement our planned business objectives and strategies will be significantly delayed, limited or may not occur. We cannot guarantee that we will become profitable. Even if we achieve profitability, given the competitive and evolving nature of the industry in which we operate, we may not be able to sustain or increase profitability and our failure to do so would adversely affect our business, including our ability to raise additional funds.

 

The accompanying consolidated financial statements appearing in this 10-K have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

We have no outstanding off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts. We do not engage in trading activities involving non-exchange traded contracts.

 

ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

24

 

 

ITEM 8. Financial Statements and Supplementary Data

 

ONE WORLD PRODUCTS, INC.

 

CONSOLIDATED FINANCIAL STATEMENTS

 

FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

 

TABLE OF CONTENTS

 

  Page
Report of Independent Registered Public Accounting Firm, M&K CPAS, PLLC (PCAOB ID: 2738) F-1
   
Consolidated Balance Sheets as of December 31, 2023 and 2022 F-2
   
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 F-3
   
Consolidated Statement of Stockholders’ Equity (Deficit) for the years ended December 31, 2023 and 2022 F-4
   
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-5
   
Notes to Consolidated Financial Statements F-6

 

25

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of One World Products, Inc. and subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of One World Products, Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, consolidated stockholders’ equity (deficit) and consolidated cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Convertible Preferred Stock

 

As discussed in Note 17, the Company has complex financial instruments due to the issued and outstanding preferred stock, resulting in the classification of the financial instruments outside of permanent equity due to the terms of the instruments. Given the factors, the related audit effort in evaluating management’s judgments in determining the appropriate classification was extensive and required a high degree of auditor judgment.

 

We tested the Company’s classification of the financial instruments by examining and evaluating the agreements along with management’s evaluation of the key terms and management’s disclosure of the transactions.

 

/s/ M&K CPAS, PLLC

We have served as the Company’s auditor since 2018.

Houston, TX

May 22, 2024

 

F-1
 

 

ONE WORLD PRODUCTS, INC.

CONSOLIDATED BALANCE SHEETS

 

   December 31,   December 31, 
   2023   2022 
Assets          
           
Current assets:          
Cash  $726   $11,016 
Accounts receivable   -    12,355 
Inventory   -    54,153 
Other current assets   13,156    45,943 
Total current assets   13,882    123,467 
           
Other assets   -    179,927 
Right-of-use assets   -    425,969 
Security deposits   85,000    1,449,808 
Fixed assets, net   -    988,536 
           
Total Assets  $98,882   $3,167,707 
           
Liabilities and Stockholders’ Equity (Deficit)          
           
Current liabilities:          
Accounts payable  $528,645   $798,067 
Accrued expenses   939,368    948,458 
Deferred revenues   -    11,808 
Dividends payable   196,734    137,843 
Current portion of lease liabilities   -    86,235 
Convertible note payable, related party, current maturities   750,000    - 
Notes payable, related parties, current maturities   1,146,500    99,500 
Notes payable, net of $24,136 of debt discounts at December 31, 2023   310,864    145,524 
Total current liabilities   3,872,111    2,227,435 
           
Long-term lease liability   -    341,680 
Convertible note payable, related party   -    750,000 
Notes payable, related parties, long-term portion   -    900,000 
           
Total Liabilities   3,872,111    4,219,115 
           
Series A convertible preferred stock, $0.001 par value, 500,000 shares authorized; 99,733 and 70,233 shares issued and outstanding at December 31, 2023 and 2022, respectively   997,330    702,330 
Series B convertible preferred stock, $0.001 par value, 600,000 shares authorized; 238,501 and 272,168 shares issued and outstanding at December 31, 2023 and 2022, respectively   3,577,515    4,082,520 
           
Stockholders’ Equity (Deficit):          
Preferred stock, $0.001 par value, 9,200,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022, respectively   -    - 
Common stock, $0.001 par value, 300,000,000 shares authorized; 79,827,618 and 67,202,907 shares issued and outstanding at December 31, 2023 and 2022, respectively   79,828    67,203 
Additional paid-in capital   18,414,456    17,123,603 
Subscriptions payable   45,000    - 
Accumulated other comprehensive income (loss)   42,328    (50,699)
Accumulated (deficit)   (26,929,686)   (22,976,365)
Total Stockholders’ Equity (Deficit)   (8,348,074)   (5,836,258)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $98,882   $3,167,707 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2
 

 

ONE WORLD PRODUCTS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   2023   2022 
   For the Years Ended 
   December 31, 
   2023   2022 
         
Revenues  $7,589   $125,662 
Cost of goods sold   173,122    300,757 
Gross loss   (165,533)   (175,095)
           
Operating expenses:          
General and administrative   1,289,656    1,587,017 
Professional fees   591,416    431,737 
Depreciation expense   34,266    42,287 
Total operating expenses   1,915,338    2,061,041 
           
Operating loss   (2,080,871)   (2,236,136)
           
Other income (expense):          
Sublease income   -    1,000 
Loss on sale of fixed assets   (3,290)   (9,041)
Gain on early extinguishment of lease   4,397    20,148 
Gain on early extinguishment of debt   -    121,372 
Loss on deconsolidation of foreign subsidiaries   (1,564,823)   - 
Interest income   7    38 
Interest expense   (308,741)   (956,858)
Total other expense   (1,872,450)   (823,341)
           
Net loss  $(3,953,321)  $(3,059,477)
           
Other comprehensive loss:          
Gain on foreign currency translation  $93,027   $13,648 
           
Net other comprehensive loss  $(3,860,294)  $(3,045,829)
Series A convertible preferred stock declared ($0.60 per share)   (58,891)   (38,923)
Net loss attributable to common shareholders  $(3,919,185)  $(3,084,752)
           
Weighted average number of common shares outstanding - basic and diluted   73,334,678    66,191,644 
           
Net loss per share - basic and diluted  $(0.05)  $(0.05)
           
Dividends declared per share of common stock  $0.00   $0.00 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

ONE WORLD PRODUCTS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable   Income (Loss)   Deficit   (Deficit) 
  

Series A Convertible

Preferred Stock

  

Series B Convertible

Preferred Stock

   Common Stock  

Additional

Paid-In

   Subscriptions  

Accumulated

Other

Comprehensive

   Accumulated  

Total

Stockholders’

Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable   Income (Loss)   Deficit   (Deficit) 
                                             
Balance, December 31, 2021   65,233   $652,330    238,501   $3,577,515    65,599,565   $65,600   $16,843,656   $21,725   $(64,347)  $(19,916,888)  $         (3,050,254)
                                                        
Series A convertible preferred stock sold for cash   5,000    50,000    -    -    -    -    -    -    -    -    - 
                                                        
Series B convertible preferred stock sold for cash   -    -    20,000    300,000    -    -    -    -    -    -    - 
                                                        
Series B convertible preferred stock issued as commitment fee on ELOC   -    -    13,667    205,005    -    -    -    -    -    -    - 
                                                        
Common stock issued for services   -    -    -    -    1,603,342    1,603    154,250    (21,725)   -    -    134,128 
                                                        
Amortization of common stock options issued for services   -    -    -    -    -    -    164,620    -    -    -    164,620 
                                                        
Series A convertible preferred stock dividends declared ($0.60 per share)   -    -    -    -    -    -    (38,923)   -    -    -    (38,923)
                                                        
Gain on foreign currency translation   -    -    -    -    -    -    -    -    13,648    -    13,648 
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (3,059,477)   (3,059,477)
                                                        
Balance, December 31, 2022   70,233   $702,330    272,168   $4,082,520    67,202,907   $67,203   $17,123,603   $-   $(50,699)  $(22,976,365)  $(5,836,258)
                                                        
Series A convertible preferred stock sold for cash   25,000    250,000    -    -    -    -    -    -    -    -    - 
                                                        
Series A Convertible Preferred Stock issued for services   4,500    45,000    -    -    -    -    -    45,000    -    -    45,000 
                                                        
Series B preferred stock conversions   -    -    (33,667)   (505,005)   3,366,700    3,367    501,638    -    -    -    505,005 
                                                        
Common stock issued for services   -    -    -    -